



Standard 1.12 Public Reporting of Outcomes

Breast Cancer Treatment

Incidence

According to the World Health Organization, breast cancer is the most common cancer among women worldwide, and is the second leading cause of cancer death among women. Statistics show that one in eight women in the United States will be diagnosed with breast cancer in her lifetime. Each year it is estimated that over 246,600 women, and approximately 2,600 men will be diagnosed with breast cancer in the United States. There are currently over 2.8 million breast cancer survivors alive in the United States today.

Survival


In recent years, perhaps coinciding with the decline in prescriptive hormone replacement therapy after menopause, we have seen a gradual reduction in female breast cancer incidence rates among women aged 50 and older. Death rates from breast cancer have been declining since about 1990, in part due to better screening and early detection, increased awareness, and continually improving treatment options.

McLaren Lapeer Region

The cancer program at McLaren Lapeer Region in 2014 treated 2 women under the age of 70 with Stage 2 hormone receptor negative breast cancer. The nationally recognized guideline of care for stage 2 breast cancer for women under the age of 70 with hormone receptor negative disease states that combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis.

Results from the National Cancer Data Base quality measuring tool indicates that combination chemotherapy was incorporated in to the treatment plan for each of these patients for whom it was appropriate based on their age, stage of disease, and hormone receptor testing results. These results compare very favorably with other cancer programs in Michigan and the United States.

MAC - Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability)



Conclusion

Breast cancer patients under the age of 70 with T1c, N0, or Stage IB-III hormone receptor negative disease can be assured that they will receive care at McLaren Lapeer Region that is consistent with nationally recognized standards.

References:

<http://www.nationalbreastcancer.org/breast-cancer-facts?gclid=CKb0ggfH-M8CFQcGaQodJxILPA>

<https://m.facs.org/cp3r/#comparisondetail/6441640/Breast/MAC>

<http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-by-stage>

Submitted: October 26, 2016

Sai Bikkina, MD

Cancer Committee Chair